trimetrexate has been researched along with Urinary Bladder Neoplasms in 3 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
Excerpt | Relevance | Reference |
---|---|---|
"Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important." | 2.67 | An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. ( Elson, P; Khandakar, J; Trump, DL; Witte, RS, 1994) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Roth, BJ | 1 |
Bajorin, DF | 1 |
Scher, HI | 1 |
Witte, RS | 1 |
Elson, P | 1 |
Khandakar, J | 1 |
Trump, DL | 1 |
1 review available for trimetrexate and Urinary Bladder Neoplasms
Article | Year |
---|---|
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
2 trials available for trimetrexate and Urinary Bladder Neoplasms
Article | Year |
---|---|
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Trimetrexate; Urinary Bladder Neoplasms | 1994 |
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; | 1994 |